Pancreatic Cancer
Pancreatic tumors should be profiled before COX-2 inhibitors are initiated
Published in Drug Week, April 8th, 2005
According to recent research from the United States, "cyclooxygenase 2 (COX-2) inhibitors are promising antiangiogenic agents in several preclinical models. The aim of the present study was to evaluate the effect of selective COX-2 inhibitors on vascular endothelial growth factor (VEGF) production in vitro and angiogenesis and growth of pancreatic cancer in vivo, focusing on putative differences between COX-2-negative and COX-2-positive tumors."
"VEGF production and angiogenesis in vitro were determined by enzyme-linked immunosorbent assay (ELISA) and endothelial cell...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-04-08)
More Articles from Drug Week
- Cancer Drugs
RLIP76 transported vinorelbine and mediated drug resistance in NSCLC - Menopause
Growth hormone improves symptoms of metabolic disorder in postmenopausal women - Mental Health
Abilify (aripiprazole) granted approval for new indication - Myocardial Infarction
Data support clinical benefits of GP IIb-IIIa inhibitors, Integrilin Injection - Neuroscience
Long-term effects seen with use of Agilect in Parkinson disease patients - Acinetobacter Infection
Risk factors identified for multidrug-resistant A. baumannii infection - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
